We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App





Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology

By LabMedica International staff writers
Posted on 15 Nov 2023
Print article
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)

Greiner Bio-One (Monroe, NC, USA) is highlighting its magnetic 3D (M3D) cell culture technology which opens up new possibilities in high-throughput screening at MEDICA 2023.

M3D bioprinting combined with cell-repellent surfaces is a superior technology for enabling the miniaturization and speed needed for high-throughput screening. M3D bioprinting enables the uniform generation and ease of manipulation of spheroids/organoids for high-throughput screening by directing magnetized cells to assemble in a controllable size within a shorter culture time. Thus, this technology surpasses the limitations of other high-throughput screening platforms. For improving predictiveness and reducing false positives of high-throughput screening, M3D has shown to be an effective and superior tool to power faster, cheaper, and better results. Moreover, 3D cell culture methodologies are often not easily scalable, meaning that the assumption that one technique used on primary screening is translatable into secondary ones is often inaccurate. A clear benefit for M3D has been its scalability, using the same workflow for high and low throughputs and delivering consistent.

At MEDICA 2023, Greiner Bio-One is also showcasing its safe, effective, and reliable blood collection products for hospitals and clinics. The company’s VACUETTE Safety Products ensure safety and comfort during blood sampling while protecting healthcare staff from blood-borne infections. By using safety products, staff protection is maximized and there is no risk of infection. For the safe transport of samples to the laboratory, Greiner Bio-One offers the VACUETTE – Transport Line range of transport containers of different dimensions in which the Vacuette is transported in an upright position. The transport bags are made of a special isothermal material that maintains a constant temperature of the samples. The transport system protects the samples from heat and mechanical influences. The transport bags also provide storage space for the accompanying medical documentation.

Related Links:
Greiner Bio-One

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.